Web Exclusives

For the past few years, much attention has been given to the development and US Food and Drug Administration (FDA) approval of targeted oral chemotherapy agents. As our knowledge of cancer and its molecular biology increases, many targeted oral chemotherapy agents have become available for use in clinical practice. The emergence of oral chemotherapy agents has provided alternative treatment options and allowed patients to receive cancer treatment in the convenience of their home. While there are many advantages to oral chemotherapy treatment, there are also many safety concerns. Read More ›

Although an uncommon cancer, sarcoma, which can arise in various connective tissues and therefore has many subtypes, is a frightening disease for both the young and old. For example, some types of bone cancer occur primarily in children, while others affect mostly adults. As we recognize Sarcoma Awareness Week this month, let’s delve into some statistics surrounding this multifaceted cancer.

Primary bone cancer is rare and accounts for less than 0.2% of all cancers.

It is estimated that this year alone, approximately 21,000 individuals in the United States will be diagnosed with multiple myeloma (MM), and more than 10,000 deaths will be attributed to the disease.¹ Response rates and survival have improved considerably over the past several decades, due in large part to the use of high-dose chemotherapy, stem cell transplantation, and the development and approval of the targeted agents thalidomide, lenalidomide, and bortezomib.² Although these advances have resulted in prolonged remissions and better quality of life, virtually all Read More ›

It is estimated that this year alone, approximately 21,000 individuals in the United States will be diagnosed with multiple myeloma (MM), and more than 10,000 deaths will be attributed to the disease.¹ Response rates and survival have improved considerably over the past several decades, due in large part to the use of high-dose chemotherapy, stem cell transplantation, and the development and approval of the targeted agents thalidomide, lenalidomide, and bortezomib.² Although these advances have resulted in prolonged remissions and better quality of life, virtually all Read More ›

Introduction